Table 19.
Cost-effectiveness of alendronate (cost £000/QALY gained) in women with clinical risk factors and no information on BMDa
Age (years) | Prior fracture | Secondary OP | FH | Smoking | c.s. | Alcohol |
---|---|---|---|---|---|---|
50 | 28.6 | 46.4 | 32.1 | 64.6 | 43.8 | 52.1 |
55 | 27.1 | 42.2 | 29.9 | 60.1 | 41.0 | 47.7 |
60 | 23.2 | 35.4 | 25.9 | 52.5 | 36.1 | 40.2 |
65 | 11.5 | 17.5 | 13.4 | 27.7 | 18.5 | 20.2 |
70 | 6.3 | 9.5 | 7.5 | 16.6 | 10.0 | 11.6 |
75 | 5.2 | 7.0 | c.s. | 14.8 | 6.3 | 9.8 |
80 | c.s. | c.s. | c.s. | 4.7 | c.s. | 2.2 |
Calculations are based on the UK (see text for details)
aBMI set at 26 kg/m2